Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free MRUS Stock Alerts $43.87 +1.90 (+4.53%) (As of 01:27 PM ET) Add Compare Share Share Today's Range$41.11▼$44.0050-Day Range$39.81▼$51.8252-Week Range$18.21▼$52.03Volume449,138 shsAverage Volume571,081 shsMarket Capitalization$2.57 billionP/E RatioN/ADividend YieldN/APrice Target$56.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Merus alerts: Email Address Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside32.8% Upside$56.33 Price TargetShort InterestBearish5.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.29) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector364th out of 907 stocksPharmaceutical Preparations Industry160th out of 422 stocks 4.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.61% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Merus has recently decreased by 4.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 1.9 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Merus this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.29) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -13.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -13.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 6.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesApril 25, 2024 | finance.yahoo.comWill Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should KnowApril 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - MRUSApril 25, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 24, 2024 | globenewswire.comMerus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingApril 23, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Receives Outperform Rating from William BlairApril 22, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Receives Average Recommendation of "Buy" from BrokeragesApril 10, 2024 | investing.comMerus reports progress on cancer therapy at AACR meetingApril 8, 2024 | finanznachrichten.deMerus N.V.: Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024April 25, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 8, 2024 | globenewswire.comMerus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024April 3, 2024 | finance.yahoo.comMerus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 11, 2024 | finance.yahoo.comMRUS Dec 2024 50.000 callMarch 10, 2024 | finance.yahoo.comMRUS Jan 2025 50.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 35.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 callMarch 6, 2024 | marketwatch.comGilead, Merus to Collaborate on Trispecific Antibody ResearchMarch 6, 2024 | msn.comGilead to invest in Merus as part of a research dealMarch 6, 2024 | finance.yahoo.comMerus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionMarch 6, 2024 | finance.yahoo.comGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersMarch 5, 2024 | finance.yahoo.comMerus Full Year 2023 Earnings: Misses ExpectationsMarch 4, 2024 | markets.businessinsider.comStrong Buy Rating for Merus’s Peto: Anticipating High Market Potential and Synergistic Treatment EfficacyMarch 2, 2024 | finance.yahoo.comEarnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And Analysts Are Trimming Their ForecastsMarch 1, 2024 | seekingalpha.comMerus: Positive Zenocutuzumab Data In 2024 Could Provide BLA AdvancementMarch 1, 2024 | markets.businessinsider.comMerus’s Upgraded Outlook: Buy Rating and Price Target Boost Amid Promising Drug Trials and Financial StabilityFebruary 29, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 putFebruary 29, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Merus (MRUS)February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed on Merus’s Stock Amid Strong Clinical Developments and Market PotentialSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees172Year FoundedN/APrice Target and Rating Average Stock Price Target$56.33 High Stock Price Target$69.00 Low Stock Price Target$45.00 Potential Upside/Downside+32.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-352.56% Pretax Margin-345.30% Return on Equity-50.61% Return on Assets-37.56% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual Sales$43.95 million Price / Sales56.65 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book6.88Miscellaneous Outstanding Shares58,690,000Free Float56,164,000Market Cap$2.49 billion OptionableOptionable Beta1.10 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 61)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 64)Chief Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 46)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 57)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 59)CTO & Executive VP Comp: $350.85kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPKathleen FarrenIR & Corporate Communications OfficerMore ExecutivesKey CompetitorsCorcept TherapeuticsNASDAQ:CORTRhythm PharmaceuticalsNASDAQ:RYTMArvinasNASDAQ:ARVNIndiviorNASDAQ:INDVJanux TherapeuticsNASDAQ:JANXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 1,590 shares on 4/18/2024Ownership: 0.003%Medicxi Ventures Management Jersey LtdSold 430,972 shares on 4/15/2024Ownership: 1.992%Wellington Management Group LLPSold 725,844 shares on 3/5/2024Ownership: 3.472%Sierra Summit Advisors LLCBought 8,049 shares on 2/22/2024Ownership: 0.014%Great Point Partners LLCBought 20,000 shares on 2/15/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions Should I buy or sell Merus stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price target for 2024? 11 Wall Street research analysts have issued twelve-month price objectives for Merus' stock. Their MRUS share price targets range from $45.00 to $69.00. On average, they expect the company's stock price to reach $56.33 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2024? Merus' stock was trading at $27.50 at the beginning of 2024. Since then, MRUS stock has increased by 54.3% and is now trading at $42.42. View the best growth stocks for 2024 here. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) issued its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.38. The biotechnology company had revenue of $8.94 million for the quarter, compared to analyst estimates of $10.43 million. Merus had a negative trailing twelve-month return on equity of 50.61% and a negative net margin of 352.56%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Tema Oncology ETF (CANC), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and BlackRock Future Health ETF (BMED).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Medicxi Ventures Management Jersey Ltd (1.99%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRUS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.